Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/500 mg

Dapagliflozin and Metformin Extended-Release Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›Strength being verifiedDapagliflozin Propanediol Hydrate›Strength being verified
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink, oblong film-coated bilayer tablets consisting of a fast-release layer and a slow-release layer
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202300349 · Approved 2023.01.27 · Insurance code 642507710

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two tablets of 5mg/1000mg. For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, treatment with this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Since such a change may cause alterations in blood glucose control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to help control blood sugar in adults with Type 2 diabetes through the combined use of dapagliflozin and metformin. It is administered as an adjunct to dietary and exercise therapy to enhance blood sugar control. It is especially indicated for patients who are not adequately controlled and have cardiovascular disease or risk factors. Cautionary information should be referenced from professional information. Overall, this medication is useful for improving blood sugar management in patients with Type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two tablets of 5mg/1000mg. For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, treatment with this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Since such a change may cause alterations in blood glucose control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication contains metformin hydrochloride and dapagliflozin for the management of blood sugar in patients with Type 2 diabetes. Care must be taken when taking this medication as there is a risk of a rare complication known as severe lactic acidosis. Lactic acidosis can be life-threatening, so immediate consultation with a physician is necessary if symptoms occur. Additionally, when taken with insulin or sulfonylurea medications, the risk of hypoglycemia may increase, so careful monitoring of blood sugar changes is advised. This medication should not be taken by patients with moderate or worse renal impairment, acute heart disease, severe infection, or dehydration. Particularly, the decision to administer should be based on renal function test results, requiring regular monitoring of renal function. This medication should be temporarily discontinued before and after surgery or examinations using contrast agents and resumed only after normal renal function is confirmed. Pregnant or breastfeeding women should not use this medication, and it is contraindicated in patients with certain genetic conditions such as lactose intolerance. Due to the potential for decreased fluid volume and hypotension, caution is advised for elderly patients or those on diuretics or with low blood pressure. Notify healthcare personnel immediately if symptoms of dehydration or hypotension occur. During treatment, genital and urinary infections may occur; therefore, prompt treatment is required if any infection symptoms or discomfort arise. The metformin component may result in vitamin B12 deficiency, so regular monitoring of vitamin B12 levels is recommended during prolonged use. The risk of lactic acidosis increases with alcohol consumption; therefore, it is advised to avoid or limit alcohol intake. Due to the risk of hypoglycemia, especially when combined with insulin or sulfonylureas, patients should be vigilant about hypoglycemic symptoms and may require dose adjustments as necessary. In case of overdose, seek medical help immediately for appropriate treatment, as this medication can be removed through dialysis, making prompt treatment crucial. Lastly, store this medication out of reach of children and keep it in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased creatinine clearance
  • dyslipidemia
  • increased blood creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • elevated blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Avoid storing it in excessively hot or cold environments, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, oblong film-coated bilayer tablets consisting of a fast-release layer and a slow-release layer

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.